Literature DB >> 7675669

Chemotherapy extravasation: a consequence of fibrin sheath formation around venous access devices.

D J Mayo1, D C Pearson.   

Abstract

PURPOSE/
OBJECTIVES: To describe, using two case studies, chemotherapy drug extravasation as a consequence of fibrin sheath formation. DATA SOURCES: Journal articles, textbooks, medical records, and personal experiences. DATA SYNTHESIS: Fibrin sheath formation around venous access devices (VADs) frequently leads to persistent withdrawal occlusion (PWO). While PWO often is easily managed with small doses of thrombolytic therapy (e.g., urokinase), it may result in a more serious complication, such as chemotherapy extravasation.
CONCLUSIONS: Chemotherapy should not be administered through a VAD unless a free-flowing blood return can be demonstrated. IMPLICATIONS FOR NURSING PRACTICE: Careful nursing assessment of all VADs is important to identify complications such as fibrin sheath formation. To rule out fibrin sheath formation, nurses must obtain catheter dye studies when fibrinolytic therapy fails to restore catheter function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675669

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  3 in total

1.  Indications and complications of inpatient parenteral nutrition prescribed to children in a large tertiary referral hospital.

Authors:  C Mantegazza; N Landy; G V Zuccotti; J Köglmeier
Journal:  Ital J Pediatr       Date:  2018-06-08       Impact factor: 2.638

2.  Comparison of hospital length of stay, costs, and readmissions of alteplase versus catheter replacement among patients with occluded central venous catheters.

Authors:  Frank R Ernst; Er Chen; Craig Lipkin; Darren Tayama; Alpesh N Amin
Journal:  J Hosp Med       Date:  2014-05-14       Impact factor: 2.960

Review 3.  Dexrazoxane for the treatment of chemotherapy-related side effects.

Authors:  Seppo W Langer
Journal:  Cancer Manag Res       Date:  2014-09-15       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.